AVE 9633

Drug Profile

AVE 9633

Alternative Names: Anti-CD33 TAP; Anti-CD33-DM4 immunoconjugate; huMy9-6-DM4; huMY96DM4

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; Sanofi
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD33 antigen inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Europe (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (Parenteral)
  • 11 Dec 2007 Interim efficacy and adverse events data from a Phase-I trial in Acute myeloid leukaemia presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top